Allspring Global Investments Holdings LLC Has $32.63 Million Stock Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Allspring Global Investments Holdings LLC trimmed its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 5.4% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 135,947 shares of the medical research company's stock after selling 7,790 shares during the quarter. Allspring Global Investments Holdings LLC owned approximately 0.49% of Bio-Rad Laboratories worth $32,627,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of BIO. GeoWealth Management LLC boosted its stake in Bio-Rad Laboratories by 342.9% during the 4th quarter. GeoWealth Management LLC now owns 93 shares of the medical research company's stock valued at $31,000 after purchasing an additional 72 shares during the period. Picton Mahoney Asset Management boosted its position in shares of Bio-Rad Laboratories by 55.6% during the fourth quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company's stock worth $32,000 after buying an additional 35 shares during the period. Curat Global LLC bought a new position in Bio-Rad Laboratories in the 1st quarter worth approximately $34,000. Cape Investment Advisory Inc. acquired a new stake in Bio-Rad Laboratories in the 4th quarter valued at approximately $38,000. Finally, Brown Brothers Harriman & Co. increased its position in Bio-Rad Laboratories by 2,928.6% in the 4th quarter. Brown Brothers Harriman & Co. now owns 212 shares of the medical research company's stock valued at $70,000 after acquiring an additional 205 shares during the period. Institutional investors and hedge funds own 65.24% of the company's stock.

Bio-Rad Laboratories Price Performance

Shares of Bio-Rad Laboratories stock traded up $0.91 during trading on Friday, hitting $251.56. The stock had a trading volume of 109,086 shares, compared to its average volume of 394,398. The business has a fifty day moving average of $235.85 and a two-hundred day moving average of $272.11. Bio-Rad Laboratories, Inc. has a fifty-two week low of $211.43 and a fifty-two week high of $387.99. The firm has a market cap of $6.84 billion, a P/E ratio of -3.30 and a beta of 0.95. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.99 and a quick ratio of 4.43.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical research company reported $2.54 earnings per share for the quarter, beating analysts' consensus estimates of $1.73 by $0.81. Bio-Rad Laboratories had a negative net margin of 85.16% and a positive return on equity of 4.32%. The company had revenue of $585.40 million during the quarter, compared to the consensus estimate of $573.01 million. During the same period in the prior year, the company earned $2.30 EPS. Bio-Rad Laboratories's revenue was down 4.2% on a year-over-year basis. On average, sell-side analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on BIO shares. Wells Fargo & Company decreased their price target on Bio-Rad Laboratories from $260.00 to $245.00 and set an "equal weight" rating for the company in a research note on Monday, June 9th. UBS Group decreased their target price on shares of Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Citigroup lowered their target price on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. Royal Bank Of Canada reduced their price target on shares of Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating for the company in a research note on Friday, May 2nd. Finally, Wall Street Zen cut shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Sunday, June 8th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $324.25.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.